Didactics-Adjuvant Treatment for Endometrial Cancer-Current Practice and Molecular classificationn

Adjuvant Treatment for Endometrial Cancer-Current Practice and Molecular classificationn - Part 2

Video Transcription

Video Summary

In this video, the speaker discusses the future of adjuvant treatment for endometrial cancer based on molecular profiling. They explain that current protocols are based on clinical and pathological characteristics, but a study conducted seven years ago identified four molecular subclasses of endometrial cancer. Each subgroup has different prognostic characteristics, with some having excellent prognosis and others having poor prognosis. The speaker also mentions two other research groups that classified molecular subgroups with similar correlations to prognosis. A trial based on the PORTEX-3 trial showed clear differences in prognosis between subgroups, and the P53 absent group benefited the most from chemotherapy. The speaker concludes by discussing the potential clinical implications of these findings and the ongoing research in de-escalation of treatment based on molecular profiles. Credits to Shira and the Vancouver group for their contributions.

Asset Subtitle

Shira Felder
March 2021

Keywords

adjuvant treatment

endometrial cancer

molecular profiling

molecular subclasses

prognosis